Open access · CC-BY
via OpenAlex
Targeted Protein Degradation: From Molecular Mechanisms to Emerging Therapeutic Strategies
Huaijuan Guo, Haishuang Duan, Yang Liu, Kelan Fang, Lujia Xiao, Ling Bai, Xiao Qu, Xuebing Yan, Kun Zhang
MedComm · 2026
Abstract
Targeted protein degradation (TPD) redirects endogenous protein clearance pathways to eliminate disease-associated proteins, offering an alternative to conventional occupancy-based inhibition. Advances in TPD have expanded the range of degradable targets from intracellular proteins to cell-surface and extracellular proteins, although these modalities differ in their mechanisms and delivery requirements. Translating these differences into rational degrader design and effective therapeutic strategies remains challenging. This review compares proteasome-dependent degradation, endocytosis-mediated lysosomal degradation, macroautophagy, and chaperone-mediated autophagy(definition), together with representative degrader classes and target scope. We discuss molecular factors influencing degradation efficacy, including target accessibility, selection of degradation machinery, productive complex formation, degradation kinetics, and target resynthesis. We then examine strategies for improving degrader delivery and spatiotemporal control, including local administration, molecular conjugation, conditional activation, and nanotechnology. Particular attention is given to the roles of nanomaterials in improving degrader delivery, controlling drug release, and constructing functional nanoscale degradation systems. Finally, we summarize preclinical evidence and clinical advances in oncology and nononcology indications and discuss limitations and future directions for therapeutic translation. By integrating degradation mechanisms, molecular design, delivery strategies, and pharmacological considerations, this review provides a framework for selecting TPD approaches according to target biology and disease context.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.1002/mco2.71125
- Canonical
- link ↗
- Fetched
- 2026-11-10 MST
Cite this
APA
Guo, H., Duan, H., Liu, Y., Fang, K., Xiao, L., Bai, L., Qu, X., Yan, X., & Zhang, K. (2026). Targeted Protein Degradation: From Molecular Mechanisms to Emerging Therapeutic Strategies. <em>MedComm</em>. https://doi.org/10.1002/mco2.71125
Vancouver
Guo H, Duan H, Liu Y, Fang K, Xiao L, Bai L, et al. Targeted Protein Degradation: From Molecular Mechanisms to Emerging Therapeutic Strategies. MedComm. 2026. doi:10.1002/mco2.71125.
BibTeX
@article{huaijuan2026Target,
title = {Targeted Protein Degradation: From Molecular Mechanisms to Emerging Therapeutic Strategies},
author = {Huaijuan Guo and Haishuang Duan and Yang Liu and Kelan Fang and Lujia Xiao and Ling Bai and Xiao Qu and Xuebing Yan and Kun Zhang},
journal = {MedComm},
year = {2026},
doi = {10.1002/mco2.71125},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
International journal of molecular sciences 2026
Open access · OA
Proteasome Dysfunction and Aggregation-Prone Proteins in Neurodegenerative Diseases: From Mechanisms to Therapeutic Opportunities.
International Journal of Molecular Sciences 2026
Open access · CC-BY
Proteasome Dysfunction and Aggregation-Prone Proteins in Neurodegenerative Diseases: From Mechanisms to Therapeutic Opportunities
Pharmacological research 2026
Citation only
Review article: Improving mitochondrial function: Current therapeutic perspectives in neurodegenerative diseases.
Neurobiology of Disease 2024
Open access · CC-BY
Interactions of alpha-synuclein with membranes in Parkinson's disease: Mechanisms and therapeutic strategies
Med-X 2026
Open access · CC-BY
Modulating senescence for therapeutic delivery
Ageing research reviews 2026
Citation only